TrialJournal for immunotherapy of cancer2022

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.

Paolo Andrea Zucali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.